Article (Scientific journals)
Histone deacetylases: anti-angiogenic targets in cancer therapy.
Mottet, Denis; Castronovo, Vincenzo
2010In Current Cancer Drug Targets, 10 (8), p. 898-913
Peer Reviewed verified by ORBi
 

Files


Full Text
(159) MOTTET D CURR CANCER DRUG TARGETS 2010.pdf
Publisher postprint (13.38 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Epigenetic; Histone deacetylases; tumor angiogenesis; HIF-1
Abstract :
[en] Judah Folkman was the first in 1971 to observe and report that cancer growth and dissemination were dependent on angiogenesis - the formation of new blood vessels from pre-existing vasculature. For almost 40 years, this concept has inspired generations of researchers to identify anti-angiogenic molecules that could be used therapeutically to stop blood vessels formation and starve tumors of nutrients and oxygen. Tumor angiogenesis requires complex cellular and molecular interactions between endothelial and cancer cells. In response to external stimuli such as hypoxia, cancer cells secrete pro-angiogenic factors into the extracellular matrix that activate the surrounding endothelial cells to proliferate, migrate and form new blood vessels. So, vascularization of malignant lesions depends on the expression of specific genes in both endothelial and tumor cells and accumulating evidences shows that several members of the histone deacetylase (HDAC) family play key roles in the regulation of these genes. Indeed, numerous in vitro and in vivo studies demonstrated that inhibitors of HDAC modulate angiogenic gene expression in both endothelial and cancer cells and disturb the delicate and complex balance between the collective action of pro-angiogenic factors and angiogenesis inhibitors. Thus, HDAC are currently recognized as promising targets for the development of anti-cancer drugs. This review is an effort to present and discuss the role, functions and mechanisms of action of HDAC during tumor-driven angiogenesis as well as a brief summary of the clinical status of the main HDAC inhibitors (HDACi) currently under development in cancer therapy.
Research center :
Giga-Cancer - ULiège
Disciplines :
Oncology
Biochemistry, biophysics & molecular biology
Author, co-author :
Mottet, Denis 
Castronovo, Vincenzo ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Language :
English
Title :
Histone deacetylases: anti-angiogenic targets in cancer therapy.
Publication date :
December 2010
Journal title :
Current Cancer Drug Targets
ISSN :
1568-0096
eISSN :
1873-5576
Publisher :
Bentham Science Publishers Ltd., San Francisco, United States - California
Volume :
10
Issue :
8
Pages :
898-913
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
CAC - Centre anticancéreux près l'Université de Liège asbl [BE]
Fonds Léon Fredericq [BE]
Télévie [BE]
Available on ORBi :
since 22 February 2011

Statistics


Number of views
123 (18 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
27
Scopus citations®
without self-citations
25
OpenCitations
 
25

Bibliography


Similar publications



Contact ORBi